Randomized Phase II Study of Intravenous 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (3-AP, Triapine NSC #663249) Cisplatin-Radiochemotherapy Versus Intravenous Cisplatin-Radiochemotherapy in Women Diagnosed With Stage IB-IVA Cervical Cancer and Stage II-IVA Vaginal Cancer

Trial Profile

Randomized Phase II Study of Intravenous 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (3-AP, Triapine NSC #663249) Cisplatin-Radiochemotherapy Versus Intravenous Cisplatin-Radiochemotherapy in Women Diagnosed With Stage IB-IVA Cervical Cancer and Stage II-IVA Vaginal Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2016

At a glance

  • Drugs OCX 191 (Primary) ; Cisplatin
  • Indications Cervical cancer; Vulvovaginal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 01 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 22 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Nov 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top